Single-Cell Analysis Market Report 2025

This Single-cell Analysis report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The single-cell analysis market size has grown rapidly in recent years. It will grow from $3.51 billion in 2024 to $3.94 billion in 2025 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to rising research in genomics, increased funding, biopharmaceutical R&D.

The single-cell analysis market size is expected to see rapid growth in the next few years. It will grow to $7.05 billion in 2029 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to wider application scope, rising adoption in clinical diagnostics, advancements in data analysis. Major trends in the forecast period include collaborations and partnerships, multi-omics integration, single-cell spatial analysis, automation and high-throughput technologies, ai and machine learning integration, expanding applications in neurology.

The rising emphasis on personalized medicine worldwide is driving the expansion of the single-cell analysis market. Personalized medicine is a medical approach that utilizes an individual's genetic profile to inform decisions regarding the treatment, prevention, and diagnosis of diseases specific to that person. Single-cell analysis plays a crucial role in treating various conditions by providing detailed insights into individual patient needs, the nature of the disease, and tailored treatment options. As a result, more patients are choosing personalized medicine for their care. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Consequently, the growing focus on personalized medicine is fueling market growth.

The increasing prevalence of chronic diseases is anticipated to drive the growth of the single-cell analysis market in the foreseeable future. Chronic diseases, characterized by prolonged durations and lack of preventative or vaccination-based treatment, benefit from the insights provided by single-cell analysis. This approach enables a deeper understanding of the pathophysiology of chronic illnesses, paving the way for more tailored and effective treatment options. For instance, as of March 2022, the Australian Bureau of Statistics reported that over three-quarters of Australians (78. 6%) had at least one long-term health problem, with nearly half (46. 6% or 11. 6 million) dealing with at least one chronic ailment. Thus, the increasing prevalence of chronic diseases is a driving force behind the growth of the single-cell analysis market.

Companies in the single-cell analysis market are prioritizing clinical diagnostic products like the ddSEQ Single-Cell 3' RNA-Seq Kit to support high-quality single-cell RNA sequencing. The ddSEQ Single-Cell 3' RNA-Seq Kit is specifically designed for precise RNA sequencing, offering detailed insights into gene expression within individual cells. For instance, in June 2024, Bio-Rad, a US-based global leader in life science research and clinical diagnostics, introduced the Single-Cell 3' RNA-Seq Kit for single-cell gene expression. This specialized kit is tailored for high-throughput sequencing of gene expression in individual cells, focusing on capturing the 3' end of mRNA transcripts. It allows researchers to analyze and quantify gene expression profiles at the single-cell level, making it a valuable tool in studies of cellular heterogeneity, developmental biology, and disease mechanisms. This kit provides critical insights into complex biological systems, further advancing the single-cell analysis market.

Major players in the single-cell analysis market are committed to developing innovative products to better serve their existing consumer base. In December 2022, Scale Biosciences Inc. launched ScaleBio’s scRNAseq solution, utilizing the company's proprietary combinatorial indexing technology. This solution allows for the scanning of up to 96 samples and thousands of cells in a single study, at a cost significantly lower than existing single-cell systems. The scRNAseq solution is designed for the characterization of cell lines, PBMCs, and nuclei, providing a fixation kit for sample fixation, storage, and transport.

In July 2023, Illumina, Inc., a US-based biotechnology company, acquired Fluent BioSciences for an undisclosed amount. The purpose of this acquisition is to enhance Illumina's capabilities in single-cell analysis and expand its multiomics growth strategy by integrating Fluent BioSciences' innovative and accessible technology. Fluent BioSciences, also based in the US, focuses on advancing technologies for single-cell analysis, with a particular emphasis on creating scalable and innovative solutions that facilitate genomic research and enable researchers to conduct detailed studies at the single-cell level.

Major companies operating in the single-cell analysis market include Becton Dickinson and Company, Merck KGAA, QIAGEN N. V., Thermo Fisher Scientific Inc., Illumina Inc., Standard BioTools Inc., 10X Genomics Inc., Bio-Rad Laboratories Inc., Novogene Corporation Limited, Agilent Technologies Inc., Sartorius AG, Luminex Corporation, Fluxion Biosciences Inc., Oxford Nanopore Technologies Ltd., 1CellBio Inc., 3D Biomatrix Inc., ACEA Biosciences Inc., Akoya Biosciences Inc., Berkeley Lights Inc., Bio-Techne Corporation, Celsee Inc., Cellular Research Inc., Cytena GmbH, Dolomite Bio Limited, Drop-seq Technologies Inc., Epic Sciences Inc., Ginkgo Bioworks Inc., IsoPlexis Corporation, Menarini Silicon Biosystems S. p. A., Mission Bio Inc., NanoCellect Biomedical Inc., NemaMetrix Inc., OnRamp Bioinformatics Inc., Partek Incorporated, RareCyte Inc., Scienion AG, SeqWell Inc., Sphere Fluidics Limited, Takara Bio USA Holdings Inc.

North America was the largest region in the single-cell analysis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single-cell analysis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the single-cell analysis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Single-cell analysis involves the study of transcriptomics, genomics, proteomics, cell interactions, and metabolomics at the individual cell level. This field aids in standardizing and automating workflows to gather information crucial for treating various diseases, including cancer. Activities in single-cell analysis revolve around research and experimental development in this specialized area.

The primary categories of single-cell analysis include consumables and instruments. Consumables are employed in tasks such as exosome analysis, genetic exploration, and isolation of RNA and DNA. The workflow of single-cell analysis comprises single-cell isolation and library preparation, downstream analysis, and data analysis. Techniques utilized in this process encompass flow cytometry, next-generation sequencing, polymerase chain reaction (PCR), microscopy, mass spectrometry, among others. Single-cell analysis finds applications in diverse areas such as cancer research, immunology, neurology, stem cell studies, non-invasive prenatal diagnosis, in-vitro fertilization, and more. The end-users of single-cell analysis include academic and research laboratories, biotechnology and pharmaceutical companies, as well as hospital and diagnostic laboratories.

The single-cell analysis market research report is one of a series of new reports that provides single-cell analysis market statistics, including single-cell analysis industry global market size, regional shares, competitors with a single-cell analysis market share, detailed single-cell analysis market segments, market trends and opportunities, and any further data you may need to thrive in the single-cell analysis industry. This single-cell analysis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The single-cell analysis market includes revenues earned by entities by providing services such as antibody-based methods, fluorescent protein-based methods, and mass-spectroscopy based methods. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.